Navigation Links
Environmental Tectonics Corporation Announces Additional Hyperbaric Monoplace Chamber Sale to St. John Wound Center

SOUTHAMPTON, Pa., June 18 /PRNewswire-FirstCall/ -- Environmental Tectonics Corporation's (OTC Bulletin Board: ETCC) ("ETC" or the "Company") BioMedical Division today announced the sale of an additional BARA-MED(R)XD monoplace hyperbaric oxygen chamber to St. John Wound Center, Tulsa, Oklahoma, USA. The state-of-the-art monoplace chamber is among the first computer-controlled hyperbaric chambers to be placed into service in Oklahoma.

Hyperbaric chambers are used in Hyperbaric Oxygen Therapy (HBOT), which is a non-invasive procedure where the patient breathes 100% oxygen while fully enclosed in a specially designed chamber at increased atmospheric pressure. HBO is the primary treatment for carbon monoxide poisoning, arterial gas embolism and decompression sickness. It is also used to promote and support healing in the management of conditions in which oxygen transport to the tissues has been disrupted by traumatic injury, infection, inflammation, or edema.

St. John Health System operates hospitals in Tulsa, Owasso, Sapulpa and Bartlesville. A fifth affiliate hospital is under construction in Broken Arrow, Okla., with completion scheduled for 2010.

"The staff of the St. John Wound Center is committed to the treatment of the whole patient, not just the wound," said Dr. Lam Le, Medical Director of the St. John Wound Center. "We work closely with specialists and primary care physicians to provide a complete care plan for optimal wound healing to address the specific needs of each patient."

All ETC BioMedical monoplace chambers include O.S.C.A.R. (TM) (Operating System for Control And Recordkeeping), ETC's unique 4th generation, time-honored computerized operating system. O.S.C.A.R. includes a patient friendly pressurization alternative (Smooth Ride(TM)) that minimizes complications due to middle ear and sinus barotraumas without increasing compression time, programmable treatment protocols and more. As an added safety feature, ETC's chambers feature a full manual override system to avoid premature termination of treatment protocol as a result of power outages.

Gene Davis, President of ETC's BioMedical Division, commented, "Placement of the third chamber at this facility is a further indication that ETC chambers are in high demand for both quality and technology."

ETC is witnessing an increased demand from hospitals and wound care clinics that recognize President Obama's mandate for Electronic Medical Records (EMR). O.S.C.A.R. addresses this important initiative.

ETC was incorporated in 1969 in Pennsylvania and this year we will celebrate our 40th anniversary. Our core technologies include the design, manufacture and sale of Training Services (TSG) which includes (1) software driven products and services used to create and monitor the physiological effects of flight; (2) high performance jet tactical flight simulation; (3) driving and disaster simulation systems, and Control Systems (CSG) which includes: (1) steam and gas sterilization; (2) testing and simulation devices for the automotive industry; (3) hyperbaric and hypobaric chambers. Product categories included in TSG are Aircrew Training Systems (ATS) and flight simulators, disaster management systems and entertainment applications. CSG includes sterilizers, environmental control devices and hyperbaric chambers along with parts and service support.

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are based on ETC's current expectations and projections about future events. These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions about ETC and its subsidiaries that may cause actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.

These forward-looking statements include statements with respect to the Company's vision, mission, strategies, goals, beliefs, plans, objectives, expectations, anticipations, estimates, intentions, financial condition, results of operations, future performance and business of the company, including but not limited to, (i) potential additional funding by H.F. Lenfest, a member of our Board of Directors and a significant shareholder and PNC Bank, (ii) the trading of the Company's common stock on the Over-the-Counter Bulletin Board (iii) projections of revenues, costs of materials, income or loss, earnings or loss per share, capital expenditures, growth prospects, dividends, capital structure, other financial items and the effects of currency fluctuations, (iv) statements of our plans and objectives of the Company or its management or Board of Directors, including the introduction of new products, or estimates or predictions of actions of customers, suppliers, competitors or regulatory authorities, (v) statements of future economic performance, (vi) statements of assumptions and other statements about the Company or its business, (vii) statements made about the possible outcomes of litigation involving the Company, (viii) statements regarding the Company's ability to obtain financing to support its operations and other expenses, and (ix) statements preceded by, followed by or that include the words, "may," "could," "should," "looking forward," "would," "believe," "expect," "anticipate," "estimate," "intend," "plan," or the negative of such terms or similar expressions. These forward-looking statements involve risks and uncertainties which are subject to change based on various important factors. Some of these risks and uncertainties, in whole or in part, are beyond the Company's control. Factors that might cause or contribute to such a material difference include, but are not limited to, those discussed in the Company's Annual Report on Form 10K for the fiscal year ended February 27, 2009, in the section entitled "Risks Particular to Our Business." Shareholders are urged to review these risks carefully prior to making an investment in the Company's common stock.

The Company cautions that the foregoing list of important factors is not exclusive. Except as required by federal securities law, the Company does not undertake to update any forward-looking statement, whether written or oral, that may be made from time to time by or on behalf of the Company.

    Contact: Duane D. Deaner, CFO
    Tel: 215-355-9100 (ext. 1203)   Fax: 215-357-4000
    ETC - Internet Home Page:

SOURCE Environmental Tectonics Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Sigma-Aldrich and Lab Manager Magazine Present Webinar On Laboratory Environmental, Health and Safety Compliance Strategies
2. Landfill mining reduces environmental impact of growing waste
3. Landfill mining reduces environmental impact of growing waste
4. Caliper Life Sciences Awarded National Institute of Environmental Health Services Contract Valued to $7.0 Million
5. Environmental Tectonics Corporations BioMedical Division Announces New Contract
6. Environmental Tectonics Corporation Announces Sale of Monoplace Hyperbaric Chambers
7. NanoLogixs Hydrogen-From-Waste Technology at Welchs Foods Featured on Environmental Radio Program
8. Nanotechs health, environmental impacts worry scientists and the public
9. White Paper Details Environmental Health & Safety Compliance Strategies for Laboratories
10. Environmental Operating Solutions Completes Initial Tranche of $2.5 Million Institutional Financing
11. Environmental Power Announces Opening of New Corporate Headquarters in Tarrytown, NY
Post Your Comments:
(Date:11/25/2015)... CITY , Nov. 25, 2015 /PRNewswire/ - Aeterna ... affirms that its business and prospects remain fundamentally ... , Zoptrex™ (zoptarelin doxorubicin) recently received DSMB recommendation ... to completion following review of the final interim ... Phase 2 Primary Endpoint in men with heavily ...
(Date:11/25/2015)... , November 25, 2015 ... Research Report is a professional and in-depth study ...      (Logo: ) , ... of the industry including definitions, classifications, applications and ... provided for the international markets including development trends, ...
(Date:11/24/2015)... HILLS, N.J. (PRWEB) , ... November 24, 2015 , ... ... as the recipient of the 2016 USGA Green Section Award. Presented annually since 1961, ... golf through his or her work with turfgrass. , Clarke, of Iselin, ...
(Date:11/24/2015)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) ... quarter ended September 30, 2015. Amounts, unless specified ... under International Financial Reporting Standards ("IFRS"). ... Andrew Rae , President & CEO of iCo ... value enriching for this clinical program, but also ...
Breaking Biology Technology:
(Date:11/17/2015)... 2015 Paris , ... --> Paris , qui s,est tenu ... le leader de l,innovation biométrique, a inventé le premier ... empreintes sur la même surface de balayage. Jusqu,ici, deux ... pour les empreintes digitales. Désormais, un seul scanner est ...
(Date:11/17/2015)... SOUTH EASTON, Mass. , Nov. 17, 2015 /PRNewswire/ ... "Company"), a leader in the development and sale of ... to the worldwide life sciences industry, today announced it ... closing of its $5 million Private Placement (the "Offering"), ... Offering to $4,025,000.  One or more additional closings are ...
(Date:11/12/2015)... 12, 2015  A golden retriever that stayed healthy ... (DMD) has provided a new lead for treating this ... Broad Institute of MIT and Harvard and the University ... Cell, pinpoints a protective gene ... disease,s effects. The Boston Children,s lab of Lou ...
Breaking Biology News(10 mins):